WallStreetZenWallStreetZen

NASDAQ: BMRN
Biomarin Pharmaceutical Inc Stock

$112.18-0.02 (-0.02%)
Updated Feb 6, 2023
BMRN Price
$112.18
Fair Value Price
$115.24
Market Cap
$20.85B
52 Week Low
$70.73
52 Week High
$117.77
P/E
249.29x
P/B
4.56x
P/S
7.83x
PEG
2.27x
Dividend Yield
N/A
Revenue
$2.01B
Earnings
$83.91M
Gross Margin
76.3%
Operating Margin
5.81%
Profit Margin
4.2%
Debt to Equity
0.37
Operating Cash Flow
$180M
Beta
0.89
Next Earnings
Feb 21, 2023
Ex-Dividend
N/A
Next Dividend
N/A

BMRN Overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BMRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BMRN ($112.18) is undervalued by 2.66% relative to our estimate of its Fair Value price of $115.24 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BMRN ($112.18) is not significantly undervalued (2.66%) relative to our estimate of its Fair Value price of $115.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BMRN ($112.18) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BMRN due diligence checks available for Premium users.

Be the first to know about important BMRN news, forecast changes, insider trades & much more!

BMRN News

Valuation

BMRN fair value

Fair Value of BMRN stock based on Discounted Cash Flow (DCF)
Price
$112.18
Fair Value
$115.24
Undervalued by
2.66%
BMRN ($112.18) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BMRN ($112.18) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BMRN ($112.18) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BMRN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
249.29x
Industry
11.5x
Market
14.99x
BMRN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BMRN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

BMRN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.56x
Industry
5.06x
BMRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BMRN price to earnings growth (PEG)

For valuing profitable companies with growth potential
BMRN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

BMRN's financial health

Profit margin

Revenue
$505.3M
Net Income
-$6.7M
Profit Margin
-1.3%
BMRN's Earnings (EBIT) of $116.75M... subscribe to Premium to read more.
Interest Coverage Financials
BMRN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$6.3B
Liabilities
$1.7B
Debt to equity
0.37
BMRN's short-term assets ($2.68B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BMRN's short-term assets ($2.68B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BMRN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BMRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$158.3M
Investing
-$23.4M
Financing
$7.5M
BMRN's operating cash flow ($180.30M)... subscribe to Premium to read more.
Debt Coverage Financials

BMRN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BMRN$20.85B-0.02%249.29x4.56x
ARGX$20.55B+0.63%-21.24x6.85x
INCY$18.77B+0.90%21.30x4.44x
RPRX$23.24B-1.77%33.57x2.23x
SGEN$25.25B-1.45%-39.42x8.95x

Biomarin Pharmaceutical Stock FAQ

What is Biomarin Pharmaceutical's quote symbol?

NASDAQ: BMRN) Biomarin Pharmaceutical trades on the NASDAQ under the ticker symbol BMRN. Biomarin Pharmaceutical stock quotes can also be displayed as NASDAQ: BMRN.

If you're new to stock investing, here's how to buy Biomarin Pharmaceutical stock.

What is the 52 week high and low for Biomarin Pharmaceutical (NASDAQ: BMRN)?

(NASDAQ: BMRN) Biomarin Pharmaceutical's 52-week high was $117.77, and its 52-week low was $70.73. It is currently -4.75% from its 52-week high and 58.6% from its 52-week low.

How much is Biomarin Pharmaceutical stock worth today?

(NASDAQ: BMRN) Biomarin Pharmaceutical currently has 185,848,915 outstanding shares. With Biomarin Pharmaceutical stock trading at $112.18 per share, the total value of Biomarin Pharmaceutical stock (market capitalization) is $20.85B.

Biomarin Pharmaceutical stock was originally listed at a price of $13.00 in Jul 26, 1999. If you had invested in Biomarin Pharmaceutical stock at $13.00, your return over the last 23 years would have been 762.92%, for an annualized return of 9.82% (not including any dividends or dividend reinvestments).

How much is Biomarin Pharmaceutical's stock price per share?

(NASDAQ: BMRN) Biomarin Pharmaceutical stock price per share is $112.18 today (as of Feb 6, 2023).

What is Biomarin Pharmaceutical's Market Cap?

(NASDAQ: BMRN) Biomarin Pharmaceutical's market cap is $20.85B, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biomarin Pharmaceutical's market cap is calculated by multiplying BMRN's current stock price of $112.18 by BMRN's total outstanding shares of 185,848,915.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.